ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evonik Will Acquire Lilly API Facility

by Michael McCoy
October 19, 2009 | APPEARED IN VOLUME 87, ISSUE 42

Evonik Industries has agreed to acquire Eli Lilly & Co.'s Tippecanoe Laboratories facility in Lafayette, Ind., a manufacturer of active pharmaceutical ingredients (APIs) and precursors that employs about 700 people. In addition, Evonik and Lilly will enter a nine-year agreement under which Evonik will make APIs and intermediates for certain Lilly products. Lilly says it is selling the site because of upcoming patent expirations; a decision to purchase, rather than make, many late-stage chemical intermediates; and the evolution of its pipeline toward biotechnology medicines. It will take a 23-cent-per-share charge in the third quarter to account for the sale. Evonik CEO Klaus Engel says the purchase "substantially boosts" his firm's exclusive synthesis business. The firm already has pharmaceutical ingredient plants in Europe and Asia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment